From fragile skin to living medicine: Lessons from RDEB

In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Mark Lowdell, CSO & Co-Founder, INmuneBio Inc

Vishwas Seshadri, CEO & Director, Abeona Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Poddgruvan

From fragile skin to living medicine: Lessons from RDEB

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

The Golden Triangle and the gaps: Rethinking UK biotech

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Portugal, Spain and the new biotech frontier

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Rethinking hair loss treatment

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

France’s biotech ecosystem: science, capital and scale